Recursion Pharmaceuticals Azioni (NASDAQ: RXRX)

Recursion Pharmaceuticals

RECURSION PHARMACEUTICALS-A

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Jim Cramer

Long Ideas

News

Penny Stocks

Markets

Media

Trading Ideas

ABTC

BROS

RXRX

Il popolare conduttore TV boccia senza mezzi termini il titolo di un&#39;azienda tech emergente, sollevando forti preoccupazioni sul suo futuro.

American Bitcoin è una &#34;totale speculazione&#34; secondo Jim Cramer

Pharmacy,,Pills,And,Box,With,Healthcare,Store,,Shelf,And,Prescription

Short Ideas

Pre-Market Outlook

MEDP

Hanno registrato rally impressionanti, ma ora un indicatore tecnico suona un campanello d&#39;allarme. Ecco di chi si tratta.

È ora di vendere? 2 titoli del settore sanitario che potrebbero esplodere

Fiserv,Office,In,Brookfield,,Wisconsin,,Usa,-,May,3,,2023.

First Trust Advantage Preferred Income Fund

RGTI

SMCI

&#34;Mad Money&#34;: quali azioni premiare e quali scartare secondo l&#39;esperto di Wall Street? Una bussola per orientarsi tra le sue valutazioni.

Jim Cramer svela le sue scelte: 2 titoli da comprare subito e 1 da evitare

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Press Releases

Recursion to Participate in Upcoming Investor Conferences

Small Cap

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

General

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Opinion

AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors

Health Care

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Earnings

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

ASTH

AVAI

BFLY

MDAI

MSFT

OABI

ORCL

RLYB

TREN

TVGN

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Cidara Therapeutics

Celcuity

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Cogent Biosciences

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

ImmunityBio

IDEAYA Biosciences

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Veracyte

Needham

Morgan Stanley

Leerink Partners

Keybanc

Jefferies

Screenshot 2025-09-08 at 3.59.27 PM

Biotech

BDRX

Tempest Therapeutics, Inc. - Common Stock

TPST

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled

BDRX-logo

PVLA

How Biodexa Is Racing To Get Its Phase 3 Program In FAP Under Way And Gain First-Mover Advantage In A $7B Addressable Market

Comments

Recursion Pharmaceuticals

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO